RBC-Specific CD47 pruning confers protection and underlies the transient anemia in patients treated with anti-CD47 antibody 5F9 by Chen, J, McKenna, K, Choi, T, Duan, J, Brown, L, Stewart, J, Sompalli, K, Vyas, P, Schrier, S, Majeti, R, Weissman, I, Elrod, K, Chao, M, Takimoto, C, Liu, J, Volkmer, J

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS) by Chen, J, Johnson, L, McKenna, K, Choi, T, Duan, J, Feng, D, Tsai, J, Garcia-Martin, N, Sompalli, K, Maute, R, Vyas, P, Majeti, R, Takimoto, C, Liu, J, Ramsingh, G, Chao, M, Volkmer, J-P, Weissman, I

The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results by Sallman, D, Asch, A, Kambhampati, S, Al Malki, M, Zeidner, J, Donnellan, W, Lee, D, Vyas, P, Jeyakumar, D, Mannis, G, Tanaka, T, Chai-Ho, W, Larson, R, Whiteley, A, Marcucci, G, Komrokji, R, Garcia-Manero, G, Van Elk, J, Lin, M, Maute, R, Volkmer, J-P, Takimoto, C, Chao, M, Daver, N